These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 11051271

  • 1. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L, Schally AV, Nagy A, Armatis P, Szepeshazi K, Halmos G.
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [Abstract] [Full Text] [Related]

  • 2. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
    Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K.
    Cancer; 1999 Jun 15; 85(12):2608-15. PubMed ID: 10375109
    [Abstract] [Full Text] [Related]

  • 3. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 4. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM, Schally AV, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [Abstract] [Full Text] [Related]

  • 5. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
    Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K.
    Breast Cancer Res Treat; 2000 Feb 01; 59(3):255-62. PubMed ID: 10832595
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K.
    Cancer Res; 1999 Apr 15; 59(8):1947-53. PubMed ID: 10213505
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
    Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G.
    Cancer Res; 2000 Jun 01; 60(11):2996-3001. PubMed ID: 10850448
    [Abstract] [Full Text] [Related]

  • 8. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G.
    Fertil Steril; 2005 Apr 01; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [Abstract] [Full Text] [Related]

  • 9. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
    Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Westphal G, Halmos G, Engel JB.
    Cancer Res; 2005 Jul 01; 65(13):5857-63. PubMed ID: 15994963
    [Abstract] [Full Text] [Related]

  • 10. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
    Szepeshazi K, Schally AV, Halmos G.
    Int J Oncol; 2007 Jun 01; 30(6):1485-92. PubMed ID: 17487370
    [Abstract] [Full Text] [Related]

  • 11. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
    Krebs LJ, Wang X, Pudavar HE, Bergey EJ, Schally AV, Nagy A, Prasad PN, Liebow C.
    Cancer Res; 2000 Aug 01; 60(15):4194-9. PubMed ID: 10945629
    [Abstract] [Full Text] [Related]

  • 12. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G, Engel JB.
    Clin Cancer Res; 2005 Aug 01; 11(15):5549-57. PubMed ID: 16061872
    [Abstract] [Full Text] [Related]

  • 13. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K, Armatis P.
    J Natl Cancer Inst; 1997 Dec 03; 89(23):1803-9. PubMed ID: 9392622
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G.
    Prostate; 2006 Feb 01; 66(2):200-10. PubMed ID: 16173040
    [Abstract] [Full Text] [Related]

  • 15. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
    Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G, Engel JB.
    Eur J Cancer; 2005 Sep 01; 41(14):2196-202. PubMed ID: 16182122
    [Abstract] [Full Text] [Related]

  • 16. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
    Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G.
    Cancer Res; 1998 Sep 15; 58(18):4132-7. PubMed ID: 9751625
    [Abstract] [Full Text] [Related]

  • 17. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB, Keller G, Schally AV, Halmos G, Hammann B, Nagy A.
    Clin Cancer Res; 2005 Mar 15; 11(6):2408-15. PubMed ID: 15788692
    [Abstract] [Full Text] [Related]

  • 18. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G, Gründker C.
    Oncol Rep; 2011 May 15; 25(5):1481-7. PubMed ID: 21331448
    [Abstract] [Full Text] [Related]

  • 19. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
    Kiaris H, Schally AV, Nagy A, Sun B, Szepeshazi K, Halmos G.
    Clin Cancer Res; 2000 Feb 15; 6(2):709-17. PubMed ID: 10690557
    [Abstract] [Full Text] [Related]

  • 20. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
    Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K.
    Prostate; 1999 Feb 01; 38(2):151-8. PubMed ID: 9973101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.